ribavirin has been researched along with Body Weight in 72 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (6.94) | 18.7374 |
| 1990's | 2 (2.78) | 18.2507 |
| 2000's | 37 (51.39) | 29.6817 |
| 2010's | 26 (36.11) | 24.3611 |
| 2020's | 2 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, ML; Li, H; Qin, YJ; Zhou, XN | 1 |
| Dai, YL; Li, KW; Li, Y; Liang, YY; Niu, FJ; Wan, XH; Wang, YY; Wei, HC; Zhou, CZ | 1 |
| Chen, Z; Li, GW; Wang, BL; Zhang, SJ | 1 |
| Barrett, L; Bon, D; Chavez, J; Dewar, R; Fauci, AS; Fishbein, D; Gu, W; Herrmann, E; Heytens, L; Highbarger, H; Kleiner, D; Kohli, A; Kotb, C; Kottilil, S; Kwan, R; Lee, YJ; Masur, H; McHutchison, J; Meissner, EG; Nelson, A; Osinusi, A; Polis, MA; Proschan, M; Shivakumar, B; Silk, R; Sneller, M; Subramanian, M; Symonds, WT; Talwani, R; Teferi, G; Wood, BJ; Wroblewski, S; Zhang, X | 1 |
| Kawano, A; Miyagi, Y; Nomura, H; Tanimoto, H; Yamashita, N | 1 |
| Buller, RM; Spencer, JF; Tollefson, AE; Toth, K; Wold, WS; Ying, B | 1 |
| Anderson, PL; Baouchi-Mokrane, F; Burton, JR; D'Argenio, DZ; Everson, GT; Hammond, KP; Kiser, JJ; Rower, JE; Urban, TJ; Wu, LS | 1 |
| Chang, JJ; Chien, CH; Chien, RN; Hu, CC; Lin, CL | 1 |
| Besheer, M; El-Karaksy, HM; El-Raziky, MS; Mogahed, EA; Mubarak, S; Saleh, D | 1 |
| Chen, DS; Chen, PJ; Chuang, WL; Dai, CY; Huang, CF; Huang, JF; Kao, JH; Liang, CC; Lin, CL; Lin, JW; Liu, CH; Liu, CJ; Su, TH; Yang, HC; Yang, SS; Yu, ML | 1 |
| Anzai, K; Eguchi, Y; Fujimoto, K; Iwane, S; Kawaguchi, Y; Kawazoe, S; Kuwashiro, T; Mizuta, T; Nakashita, S; Oeda, S; Otsuka, T; Oza, N; Ozaki, I; Takahashi, H | 1 |
| Albrecht, JK; Alonso, E; Ciocca, M; Gonzalez, T; Goodman, Z; Haber, B; Jackson, B; Lacaille, F; Lang, T; Noviello, S; Pedreira, A; Rodriguez-Baez, N; Yang, Z | 1 |
| Hamer, C | 1 |
| Jiménez-Rivera, J; Marxuach-Cuétara, A; Ortiz-Lasanta, G; Purcell-Arevalo, D; Ríos-Bedoya, CF; Rodríguez-Torres, M | 1 |
| Alsiö, A; Buhl, MR; Christensen, P; Dhillon, AP; Färkkilä, M; Hellstrand, K; Lagging, M; Langeland, N; Leutscher, P; Mørch, K; Norkrans, G; Pedersen, C; Westin, J | 1 |
| Anand, B; Barange, K; Diago, M; Govindarajan, S; Hooper, G; Lin, A; Morgan, T; Rodriguez-Torres, M; Shiffman, M; Suter, F | 1 |
| Chuang, WL; Dai, CY; Huang, JF; Yu, ML | 1 |
| Ichijo, T; Joshita, S; Kiyosawa, K; Komatsu, M; Matsumoto, A; Shirakawa, H; Tanaka, E; Tanaka, N; Umemura, T; Yoshizawa, K | 1 |
| Ganslmayer, M; Hahn, EG; Herold, C; Zopf, S | 1 |
| Ben-Ari, Z; Braun, M; Cohen, M; Cohen-Ezra, O; Katz, L; Manhaim, V; Rotman, Y; Tur-Kaspa, R | 1 |
| Basso, M; Giannini, EG; Picciotto, A; Savarino, V | 1 |
| Albrecht, JK; Alonso, E; Bortolotti, F; Brass, C; Broue, P; Calzado, MA; Ciocca, M; Galoppo, M; Gonzalez, T; Goodman, Z; Huber, WD; Hunter, B; Jara, P; Kerkar, N; Kullmer, U; Lacaille, F; Lachaux, A; Lang, T; Neigut, D; Noviello, S; Pedreira, A; Pollack, H; Ramakrishna, J; Ribes-Koninckx, C; Rodriguez-Baez, N; Shelton, M; Sniukiene, V; Valle-Segarra, AD; Wirth, S; Xu, CR; Zancan, L; Zheng, H | 1 |
| Heathcote, EJ; Mazzulli, T; Pattullo, V; Ravindran, NC; Wong, DK | 1 |
| Chuang, WL; Dai, CY; Huang, CF; Huang, JF; Yu, ML | 1 |
| Bacon, BR; Chun, E; Halliman, D; Hammond, J; Hassanein, T; Heise, J; Lawitz, E; Muir, AJ; Poordad, F; Shiffman, ML | 1 |
| Abdurakhmanov, D; Bakulin, I; Cheinquer, H; Geyvandova, N; Harrison, SA; McKenna, M; Morozov, V; Rabbia, M; Reddy, KR; Rodriguez-Torres, M; Shiffman, ML; Silva, GF; Stanciu, C; Thommes, JA | 1 |
| Ehleben, C; Pearlman, BL | 1 |
| Chung, RT; Di Bisceglie, AM; Hassanein, T; Lentz, E; Poordad, FF; Prabhakar, A; Zhou, X | 1 |
| Afdhal, N; Conjeevaram, HS; Everhart, JE; Hoofnagle, JH; Howell, CD; Wahed, AS | 1 |
| Abu-Mouch, S; Buggisch, P; Chen, R; Cornberg, M; Faruqi, R; Hinrichsen, H; Horban, A; Ilan, Y; Klinker, H; Lurie, Y; Manns, M; Mauss, S; Merican, I; Müller, TH; Pedicone, LD; Rössle, M; Sood, A; Wedemeyer, H; Welsch, C; Zeuzem, S | 1 |
| Chen, L; Dou, J; Guo, Q; Su, Z; Wang, H; Zhou, C; Zhou, H; Zhou, W | 1 |
| Adinolfi, LE; Lonardo, A; Loria, P; Restivo, L; Zampino, R | 1 |
| Baron, A; Brochot, E; Capron, D; Castelain, S; Coulouarn, C; Descamps, V; Duchaussoy, I; Duverlie, G; François, C; Nguyen-Khac, E | 1 |
| Balistreri, W; Barton, BA; Duggan, C; Gonzalez-Peralta, RP; Haber, B; Jonas, MM; Lobritto, S; Mitchell, PD; Mohan, P; Molleston, JP; Murray, KF; Narkewicz, MR; Rosenthal, P; Schwarz, KB; Shepherd, JA | 1 |
| Abdurakhmanov, D; Bakulin, I; Cheinquer, H; Connell, EV; Harrison, SA; Mazur, W; McKenna, M; Messinger, D; Reddy, KR; Rodriguez-Torres, M; Shiffman, ML; Silva, GF; Tatsch, F | 1 |
| Cai, L; Dowling, TC; Howell, CD; Jin, R; McHutchison, JG; Tan, M | 1 |
| Jang, JY; Jeong, SW; Kim, BS; Kim, Hi; Kim, HS; Kim, SG; Kim, SH; Kim, YS; Lee, SW; Park, SS; Seo, YR; You, BC | 1 |
| Hézode, C | 1 |
| Friedlander, L; Kondaveeti, K; Van Thiel, DH | 1 |
| Hrachovec, J; Patel, P | 1 |
| Bailey, KW; Beadle, JR; Hostetler, KY; Sidwell, RW; Smee, DF; Wong, MH | 1 |
| Dadgostari, S; Lin, CC; Vitarella, D; Xu, C; Yeh, LT | 1 |
| Almasio, PL | 1 |
| Bruno, R; Ciappina, V; Filice, G; Maiocchi, L; Patruno, S; Sacchi, P; Zocchetti, C | 1 |
| Boyer, N; Cazals-Hatem, D; Consigny, Y; Degott, C; Marcellin, P; Marrache, F; Martinot, M; Ripault, MP; Valla, D | 1 |
| D'Souza, UJ; Kumar, G; Narayan, P; Narayana, K | 1 |
| Helbling, B; Mülhaupt, B; Telser, H; Zweifel, P | 1 |
| Baczkowski, A; Geffner, M; González-Peralta, RP; Gupta, S; Haber, B; Jonas, MM; Kelly, DA; Lang, T; Laughlin, M; Lurie, Y; Martin, S; Mieli-Vergani, G; Molleston, J; Murray, KF; Shelton, M | 1 |
| Kakizaki, S; Kanda, D; Mori, M; Sato, K; Sohara, N; Suzuki, H; Takagi, H | 1 |
| Husa, P; Slesinger, P; Stroblová, H; Svobodník, A | 1 |
| Bräu, N; Eldeiry, LS; Greenberg, PD; Naqvi, Z; Rosman, AS | 1 |
| Alvarez, D; Ball, L; Brau, N; Dieterich, DT; Moorehead, L; Sulkowski, MS | 1 |
| Chang, KC; Changchien, CS; Chen, CH; Hu, TH; Hung, CH; Kee, KM; Lee, CM; Lu, SN; Tseng, PL; Wang, JH; Yen, YH | 1 |
| Brown, RS | 1 |
| Bonkovsky, HL; Di Bisceglie, AM; Dienstag, JL; Everson, GT; Ghany, MG; Gretch, DR; Lee, WM; Lindsay, KL; Lok, AS; Morgan, TR; Shiffman, ML; Wright, EC | 1 |
| Araújo, E; Barone, AA; Borges, A; Coelho, HS; Corrêa-Giannella, ML; Ferraz, ML; Focaccia, R; Gonçales, FL; Gonçales, N; Lobato, C; Oliveira, U; Paixao, J; Perez, R; Rosa, H; Vigani, A; Vila, R; Weirich, J | 1 |
| Damian, D; Gheorghe, C; Gheorghe, L; Grigorescu, M; Iacob, R; Iacob, S; Sirli, R; Sporea, I | 1 |
| Han, SH; Smith, J | 1 |
| Afdhal, N; Becker, S; Bernstein, D; Brass, CA; Brown, RS; Flamm, S; Freilich, B; Godofsky, E; Griffel, LH; Jacobson, IM; Kwo, PY; Mukhopadhyay, P; Pauly, MP; Pound, D; Santoro, J; Strauss, R; Wakil, AE | 1 |
| Albert, C; Araya, V; Black, M; Brass, CA; Brown, RS; Dragutsky, MS; Freilich, B; Galler, GW; Griffel, LH; Hargrave, T; Harvey, J; Jacobson, IM; Kwo, PY; Lambiase, L; McCone, J; Siddiqui, FA | 1 |
| Brown, RS; Jacobson, IM | 1 |
| Canonico, PG; Cosgriff, TM; Donovan, JC; Kastello, MD; Ross, PE; Spears, CT; Stephen, EL | 1 |
| Gupta, P; Patki, SA | 1 |
| Ambrose, MW; Gilbert, BE; Meyerson, LR; Wyde, PR | 1 |
| Bailey, KW; Sidwell, RW; Smee, DF | 1 |
| Powell, J | 1 |
| Cecil, BD | 1 |
| Arensman, JB; Hilmas, DE; Tschorn, RR | 1 |
| Divine, GW; Gilbert, BE; Knight, V; Yu, CP | 1 |
| Craig, DK; Hoffmann, SH; Parker, G; Smith, RA; Staffa, JA | 1 |
5 review(s) available for ribavirin and Body Weight
| Article | Year |
|---|---|
Metabolic alterations and chronic hepatitis C: treatment strategies.
Topics: Antiviral Agents; Body Weight; Cholesterol; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-alpha; Metabolic Syndrome; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2011 |
Consensus conference. Treatment of hepatitis C.
Topics: Adult; Aged; Alcoholism; Amantadine; Antiviral Agents; Body Weight; Child; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Graft Rejection; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Mental Disorders; Middle Aged; Monitoring, Physiologic; Quality of Life; Recurrence; Ribavirin; Risk Factors; Substance-Related Disorders; Time Factors | 2002 |
[Treatment of patients with chronic hepatitis C who never had been treated].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Biopsy; Body Weight; Clinical Enzyme Tests; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukin-2; Liver; Liver Cirrhosis; Meta-Analysis as Topic; Placebos; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Time Factors; Transaminases; Viral Load | 2002 |
Weight-based dosing: which impact on efficacy and safety of therapy?
Topics: Antiviral Agents; Body Mass Index; Body Weight; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2004 |
Customizing treatment to patient populations.
Topics: Antiviral Agents; Body Weight; Dose-Response Relationship, Drug; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Virus Replication | 2007 |
23 trial(s) available for ribavirin and Body Weight
| Article | Year |
|---|---|
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.
Topics: Antiviral Agents; Body Weight; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Interleukins; Male; Middle Aged; Prognosis; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load | 2013 |
Weight loss during telaprevir-based triple therapy due to telaprevir-induced appetite loss.
Topics: Antiviral Agents; Appetite; Body Weight; Depression; Drug Therapy, Combination; Female; Genotype; Ghrelin; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-beta; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Ribavirin; Treatment Outcome; Weight Loss | 2014 |
Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Body Weight; Erythrocytes; Female; Half-Life; Hepatitis C, Chronic; Humans; Liver Function Tests; Male; Middle Aged; Models, Statistical; Oligopeptides; Phosphorylation; Population; Ribavirin; Sex Characteristics | 2015 |
Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial.
Topics: Adult; Aged; Antiviral Agents; Body Weight; Dose-Response Relationship, Drug; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2015 |
Impact of Body Weight Reduction via Diet and Exercise on the Anti-Viral Effects of Pegylated Interferon Plus Ribavirin in Chronic Hepatitis C Patients with Insulin Resistance: A Randomized Controlled Pilot Trial.
Topics: Adult; Antiviral Agents; Body Weight; Diet; Directive Counseling; Drug Therapy, Combination; Exercise; Female; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon-alpha; Male; Middle Aged; Obesity; Pilot Projects; Prospective Studies; Ribavirin; Treatment Outcome; Viral Load; Weight Loss | 2015 |
Long-Term Follow-Up of Children Treated With Peginterferon and Ribavirin for Hepatitis C Virus Infection.
Topics: Adolescent; Antiviral Agents; Body Height; Body Mass Index; Body Weight; Child; Child, Preschool; Drug Therapy, Combination; Female; Follow-Up Studies; Growth Disorders; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2017 |
Low weight predicts neutropenia and peginterferon alfa-2a dose reductions during treatment for chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Body Mass Index; Body Surface Area; Body Weight; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Young Adult | 2009 |
High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin.
Topics: Adolescent; Antiviral Agents; Body Height; Body Weight; Child; Child Development; Child, Preschool; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2010 |
Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C.
Topics: Adolescent; Adult; Anemia, Hemolytic; Antiviral Agents; Body Weight; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2010 |
Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads.
Topics: Adult; Antiviral Agents; Body Weight; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Obesity; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2010 |
Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Body Weight; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Male; Middle Aged; Neutrophils; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C.
Topics: Adult; Body Weight; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Intention to Treat Analysis; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors | 2011 |
Pegylated interferon for chronic hepatitis C in children affects growth and body composition: results from the pediatric study of hepatitis C (PEDS-C) trial.
Topics: Adolescent; Antiviral Agents; Body Composition; Body Height; Body Mass Index; Body Weight; Child; Child, Preschool; Cohort Studies; Drug Therapy, Combination; Eating; Fatty Liver; Female; Growth Disorders; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2012 |
Retreatment of high-dose interferon (5 MU daily) nonresponders with high-dose IFN + ribavirin.
Topics: Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Retreatment; Ribavirin; Treatment Failure | 2002 |
Area-under-the-curve for peginterferon alpha-2a and peginterferon alpha-2b is not related to body weight in treatment-naive patients with chronic hepatitis C.
Topics: Antiviral Agents; Body Weight; Drug Carriers; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis.
Topics: Adult; Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Follow-Up Studies; France; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2005 |
Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.
Topics: Adolescent; Antiviral Agents; Body Height; Body Weight; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2005 |
Triple therapy of interferon and ribavirin with zinc supplementation for patients with chronic hepatitis C: a randomized controlled clinical trial.
Topics: Adult; Aged; Anti-Ulcer Agents; Antiviral Agents; Body Weight; Carnosine; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Organometallic Compounds; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Zinc; Zinc Compounds | 2006 |
Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons.
Topics: Adult; Anemia; Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Zidovudine | 2006 |
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Time Factors | 2007 |
Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Body Weight; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1.
Topics: Antiviral Agents; Black or African American; Body Weight; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2007 |
Evaluation of ribavirin in the treatment of acute hepatitis.
Topics: Adolescent; Adult; Alanine Transaminase; Aspartate Aminotransferases; Bilirubin; Body Weight; Child; Clinical Trials as Topic; Double-Blind Method; Female; Hepatitis A; Humans; Male; Middle Aged; Ribavirin; Ribonucleosides | 1982 |
44 other study(ies) available for ribavirin and Body Weight
| Article | Year |
|---|---|
[A case of chronic hepatitis C treated with sofosbuvir/velpatasvir combined with ribavirin among 3-year-old children with low body weight].
Topics: Antiviral Agents; Body Weight; Child, Preschool; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
Salvia plebeia R. Br. polysaccharides (SPP) against RSV (respiratory syncytial virus) infection: Antiviral effect and mechanisms of action.
Topics: Animals; Antiviral Agents; Body Weight; Cell Line; Cytokines; Eating; Humans; Lung; Mice; Mice, Inbred BALB C; Plant Extracts; Polysaccharides; Respiratory Function Tests; Respiratory Syncytial Virus Infections; Respiratory Syncytial Virus, Human; Ribavirin; Salvia; Tetrazolium Salts; Thiazoles; Toll-Like Receptors | 2021 |
Effect of the Haoqinqingdan decoction on damp-heat syndrome in rats with influenza viral pneumonia.
Topics: Animals; Antiviral Agents; Body Temperature; Body Weight; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Fever; Flow Cytometry; Immunologic Factors; Interferon-gamma; Interleukin-4; Lymphocyte Subsets; Orthomyxoviridae Infections; Plant Extracts; Plants, Medicinal; Pneumonia, Viral; Rats; Rats, Wistar; Ribavirin; Treatment Outcome | 2013 |
Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model.
Topics: Adenoviridae Infections; Adenoviruses, Human; Alanine Transaminase; Animals; Body Weight; Cell Line; Cidofovir; Cytosine; Disease Models, Animal; Female; Humans; Immunocompromised Host; Liver; Mesocricetus; Organophosphonates; Ribavirin; Survival Analysis; Treatment Outcome; Viral Load | 2014 |
Clearance of Hepatitis C Virus Improves Insulin Resistance During and After Peginterferon and Ribavirin Therapy.
Topics: Adult; Aged; Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Insulin Resistance; Interferon-alpha; Male; Middle Aged; Models, Biological; Ribavirin; Risk Factors; Treatment Outcome; Viral Load; Young Adult | 2015 |
Safety and Efficacy of Combined Treatment with Pegylated Interferon Alpha-2b and Ribavirin for HCV Genotype 4 in Children.
Topics: Adolescent; Antiviral Agents; Body Height; Body Weight; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combination; Female; Fever; gamma-Glutamyltransferase; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Male; Neutropenia; Neutrophils; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Surveys and Questionnaires; Treatment Outcome; Viral Load | 2016 |
The impact of combination therapy with peginterferon alpha-2a and ribavirin on the energy intake and body weight of adult hepatitis C patients.
Topics: Aged; Antiviral Agents; Appetite; Body Mass Index; Body Weight; Drug Therapy, Combination; Energy Intake; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Nausea; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Surveys and Questionnaires | 2008 |
Weight affect relapse rates in latinos with genotype 2/3 chronic hepatitis C (CHC) treated with peg IFN alfa-2a (Pegasys) 180 mcg/week and 800 mg daily of ribavirin for 24 weeks.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Body Weight; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Statistical; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Factors; Treatment Outcome | 2008 |
Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection.
Topics: Antiviral Agents; Body Weight; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors | 2008 |
Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks.
Topics: Age Factors; Body Weight; Fatty Liver; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2009 |
Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure.
Topics: Antiviral Agents; Body Weight; Dose-Response Relationship, Drug; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2008 |
Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Body Weight; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Mutation; Neutrophils; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; Th1 Cells; Th2 Cells; Treatment Outcome; Viral Load; Young Adult | 2008 |
Peginterferon alfa-2a relapse rates depend on weight-based ribavirin dosage in HCV-infected patients with genotype 1: results of a retrospective evaluation.
Topics: Adult; Antiviral Agents; Body Weight; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin | 2009 |
Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension.
Topics: Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hypertension, Portal; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2009 |
Pegylated interferon plus optimized weight-based ribavirin dosing negate the influence of weight and body mass index on early viral kinetics and sustained virological response in chronic hepatitis C.
Topics: Antiviral Agents; Body Mass Index; Body Weight; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2010 |
Hepatitis C virus genotype 2/3 patients who can receive an abbreviated course of peginterferon/ribavirin: the important role of initial ribavirin doses.
Topics: Body Weight; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors | 2010 |
Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virological response.
Topics: Antiviral Agents; Body Weight; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2010 |
Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C.
Topics: Adult; Age Factors; Antiviral Agents; Body Mass Index; Body Weight; Clinical Trials as Topic; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Multicenter Studies as Topic; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Synergistic activity of baicalein with ribavirin against influenza A (H1N1) virus infections in cell culture and in mice.
Topics: Administration, Oral; Animals; Antiviral Agents; Body Weight; Cell Culture Techniques; Cell Line; Dogs; Drug Combinations; Drug Synergism; Female; Flavanones; Influenza A Virus, H1N1 Subtype; Kidney; Lung; Mice; Mice, Inbred ICR; Orthomyxoviridae Infections; Ribavirin; Survival Rate; Viral Matrix Proteins; Virus Replication | 2011 |
The treatment response of chronically hepatitis C virus-infected patients depends on interferon concentration but not on interferon gene expression in peripheral blood mononuclear cells.
Topics: Adult; Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Gene Expression Regulation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2012 |
Intensified peginterferon α-2a dosing increases sustained virologic response rates in heavy, high viral load hepatitis C genotype 1 patients with high low-density lipoprotein.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Body Weight; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Young Adult | 2013 |
Optimum ribavirin exposure overcomes racial disparity in efficacy of peginterferon and ribavirin treatment for hepatitis C genotype 1.
Topics: Antiviral Agents; Area Under Curve; Black or African American; Body Weight; Chi-Square Distribution; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome; White People | 2012 |
A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C.
Topics: Antiviral Agents; Body Mass Index; Body Weight; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Sex Factors; Treatment Outcome | 2012 |
Weight-based ribavirin with pegylated interferon alfa 2b: benefits, risks, and the origin of the evidence.
Topics: Adult; Antiviral Agents; Body Weight; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2003 |
Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice.
Topics: Animals; Antiviral Agents; Body Weight; Brain; Cidofovir; Cytosine; Drug Evaluation, Preclinical; Heart; Liver; Lung; Mice; Mice, Inbred BALB C; Organophosphonates; Oxygen; Purines; Respiratory Tract Infections; Ribavirin; Salivary Glands; Spleen; Treatment Outcome; Vaccinia; Vaccinia virus; Viral Plaque Assay; Viremia | 2004 |
[Hepatitis C infection. Overweight virus carriers are more difficult to cure].
Topics: Antiviral Agents; Biological Availability; Body Weight; Carrier State; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Metabolic Clearance Rate; Obesity; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Viramidine demonstrates better safety than ribavirin in monkeys but not rats.
Topics: Animals; Antiviral Agents; Area Under Curve; Blood Cell Count; Body Temperature; Body Weight; Eating; Electrocardiography; Eye Diseases; Female; Hemodynamics; Macaca fascicularis; Male; Organ Size; Rats; Rats, Sprague-Dawley; Respiratory Mechanics; Ribavirin | 2004 |
The antiviral drug ribavirin reversibly affects the reproductive parameters in the male Wistar rat.
Topics: Animals; Antiviral Agents; Body Weight; Dose-Response Relationship, Drug; Genitalia, Male; Male; Organ Size; Rats; Rats, Wistar; Reproduction; Ribavirin; Spermatozoa; Testis; Testosterone | 2005 |
[Cost comparison of two combination therapies with peginterferon alfa and ribavarin for the treatment of hepatitis C].
Topics: Algorithms; Antiviral Agents; Body Weight; Cost Savings; Drug Therapy, Combination; Genotype; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
[The effect of patient's body weight, gender and baseline viral load on the efficacy of hepatitis C therapy].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sex Factors; Treatment Outcome; Viral Load | 2006 |
Decline in haemoglobin A1c values in diabetic patients receiving interferon-alpha and ribavirin for chronic hepatitis C.
Topics: Antiviral Agents; Blood Glucose; Body Weight; Diabetes Complications; Diabetes Mellitus; Erythrocyte Indices; Female; Glycated Hemoglobin; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon-alpha; L-Lactate Dehydrogenase; Male; Middle Aged; Reticulocyte Count; Retrospective Studies; Ribavirin | 2006 |
Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response.
Topics: Age Factors; Anemia; Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Sex Factors; Treatment Outcome | 2006 |
Weight-based combination therapy with peginterferon alpha-2b and ribavirin for naïve, relapser and non-responder patients with chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Body Weight; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2006 |
Efficacy, tolerability and predictive factors for early and sustained virologic response in patients treated with weight-based dosing regimen of PegIFN alpha-2b ribavirin in real-life healthcare setting.
Topics: Adult; Antiviral Agents; Body Weight; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2007 |
"True" weight-based dosing versus "flat" dosing of ribavirin: will the WIN-R please come forward?
Topics: Antiviral Agents; Black or African American; Body Weight; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; White People | 2007 |
WIN-R revisited: Response to editorial.
Topics: Antiviral Agents; Black or African American; Body Weight; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
Hematological and bone marrow effects of ribavirin in rhesus monkeys.
Topics: Animals; Blood Cells; Body Weight; Bone Marrow; Erythrocyte Count; Erythrocyte Indices; Female; Hematocrit; Hemoglobins; Macaca mulatta; Male; Ribavirin; Ribonucleosides; Thrombocytosis | 1984 |
The antiviral activity of SP-303, a natural polyphenolic polymer, against respiratory syncytial and parainfluenza type 3 viruses in cotton rats.
Topics: Animals; Antiviral Agents; Biopolymers; Body Weight; Catechin; Culture Techniques; Lung; Parainfluenza Virus 3, Human; Paramyxoviridae Infections; Plants, Medicinal; Respiratory Syncytial Viruses; Respirovirus Infections; Ribavirin; Sigmodontinae; Viral Plaque Assay | 1993 |
Treatment of cowpox virus respiratory infections in mice with ribavirin as a single agent or followed sequentially by cidofovir.
Topics: Animals; Antiviral Agents; Body Weight; Cell Line; Chlorocebus aethiops; Cidofovir; Cowpox; Cowpox virus; Cytosine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Lung; Mice; Mice, Inbred BALB C; Organophosphonates; Organophosphorus Compounds; Respiratory Tract Infections; Ribavirin; Vero Cells; Viral Plaque Assay | 2000 |
Treating hepatitis C: a clinician's perspective. Interview by Bob Roehr.
Topics: Antiviral Agents; Biopsy; Body Weight; Dose-Response Relationship, Drug; Hepatitis C; HIV Infections; Interferon Type I; Liver; Liver Transplantation; Recombinant Proteins; Ribavirin | 1998 |
Peginterferon alfa-2b plus ribavirin for chronic hepatitis.
Topics: Antiviral Agents; Body Weight; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2002 |
Effect of small-particle aerosols of rimantadine and ribavirin on pathophysiologic changes associated with A/NJ influenza in mice.
Topics: Adamantane; Aerosols; Animals; Antiviral Agents; Body Weight; Bridged-Ring Compounds; Female; Influenza A virus; Lung; Mice; Organ Size; Orthomyxoviridae Infections; Oxygen; Ribavirin; Ribonucleosides; Time Factors | 1978 |
Estimating the dosage of ribavirin aerosol according to age and other variables.
Topics: Adolescent; Adult; Aerosols; Age Factors; Body Weight; Bronchi; Child; Child, Preschool; Female; Fever; Humans; Infant; Intubation, Intratracheal; Lung; Male; Respiration; Ribavirin; Ribonucleosides; Sex Factors; Tidal Volume; Trachea | 1988 |
Inhalation toxicity of ribavirin in suckling ferrets.
Topics: Administration, Inhalation; Animals; Animals, Suckling; Body Weight; Carnivora; Female; Ferrets; Organ Size; Particle Size; Pregnancy; Ribavirin; Ribonucleosides; Therapeutic Irrigation | 1987 |